---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-073072"
form_type: "8-K"
ticker: "PFSA"
cik: "0001859807"
company_name: "Profusa, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:22:24.098336+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Profusa strategy update: $100M ELOC secured, EU launch Q1 2026, FDA submission mid-2026

## Summary
- Became public on Nasdaq July 14, 2025; strategy focused on five pillars including revenue growth and AI infrastructure.
- First distributor partner in Spain for Lumee tissue oxygen platform; EU commercial launch targeted Q1 2026.
- U.S. FDA submission planned mid-2026 with U.S. commercialization anticipated mid-2027 for oxygen monitoring.
- Continuous glucose monitoring: human validation data expected in peer-reviewed journal; pivotal studies later 2026.
- Secured $100M ELOC facility and implementing digital investment treasury plan to support growth.

## SEC filing metadata
- accession: 0001213900-25-073072
- form_type: 8-K
- ticker: PFSA
- cik: 0001859807
- company_name: Profusa, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859807/000121390025073072/0001213900-25-073072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859807/000121390025073072/ea0252144-8k_profusa.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-073072
- JSON: https://secwatch.observer/filing/0001213900-25-073072.json
- Plain text: https://secwatch.observer/filing/0001213900-25-073072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.